Guard Therapeutics obtains a granted patent from USPTO concerning ROSgard as product
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Guard Therapeutics AB (publ.) today announces that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application no. 16/085,500 directed to the biological investigational drug ROSgard as product (composition of matter). The granted patent follows the Notice of Allowance that was issued and communicated in December 2020.
The granted patent will issue as US patent no. 10,981,963 on 20 April 2021 and protects Guard Therapeutics’ lead investigational drug ROSgard as a product. The patent, which provides protection until 2037, also covers related molecules that are of similar structure to ROSgard. The granted patent further strengthens Guard Therapeutic’s patent portfolio and the commercial potential of ROSgard.
“With the USPTO granting this patent, Guard Therapeutics has obtained a valuable patent protection for ROSgard as a product in the US, one of the company’s projected key markets. The patent is an important part of the company’s integrated patent portfolio and supports the continued development of our investigational drug ROSgard” Tobias Agervald, CEO of Guard Therapeutics says.